Navigation Links
Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Date:3/3/2011

SAN DIEGO, March 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce fourth quarter and year ended December 31, 2010 financial results on Thursday, March 10, 2011 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (866) 788-0543 (domestic) or (857) 350-1681 (international), participant code 73770341. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com  and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response Letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
3. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
4. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
5. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
6. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
7. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
10. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
11. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Morgan Stanley 15 th ... hotel in New York.  Zimmer Biomet will present on ... A live webcast of the presentation can ... http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... 2017  Robert G. Szewc, M.D., is recognized by ... recognition of his contributions to the Medical field.      ... at the practice of Kidney and Hypertension Specialists, which ... hypertension solutions. He has worked in this position since ... as well as expertise in kidneys, hypertension, chronic disease ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the launch ... and easy access to essential information that offers a more comprehensive understanding of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Renal ... for people who have kidney disease. The theme “Describe a positive decision that ... Entrants needed to meet only one qualification— to have been diagnosed with ...
(Date:9/20/2017)... Houston, TX (PRWEB) , ... September 20, 2017 ... ... the date of the much-anticipated fall event , Look Awesome This Autumn ... demonstrations, personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of ... recently unveiled a redesigned website. The new site – still located at ... architects, contractors and other industry users that Garland serves. , After an ambitious ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time since going on ... positive feedback from customers trying the product for the first time, and others who ... developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at risk from multiple ...
Breaking Medicine News(10 mins):